Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.23 USD | +1.93% | +8.38% | +12.43% |
May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.43% | 472M | |
+4.24% | 111B | |
+11.47% | 105B | |
-12.98% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.29% | 16.96B | |
+3.36% | 13.7B | |
+37.14% | 12.45B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Morgan Stanley Adjusts Price Target on Fate Therapeutics to $3 From $5, Maintains Equalweight Rating